Content
List volumes -
List articles in this issue
Cutaneous Gamma/Delta T-cell Lymphoma During Treatment with Etanercept for Rheumatoid Arthritis
doi: 10.2340/00015555-0728
Authors:
Lianne Koens, Nancy J. Senff, Maarten H. Vermeer, H. Karel Ronday, Rein Willemze and Patty M. Jansen
References
Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007; 7: 35–41.
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–3158.
Lourari S, Prey S, Livideanu C, Jamard B, Lamant L, Cantagrel A, et al. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-α blocking agents: two cases. J Eur Acad Dermatol Venereol 2009; 23: 967–968.
Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149: 170–173.
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, et al. Aggressive cutaneous T-cell lymphomas after TNF-alpha blockade. J Am Acad Dermatol 2004; 51: 660–662.
Michot C, Costes V, Gerard-Dran D, Guillot B, Combes B, Dereure O. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol 2009; 160: 889–890.
Dauendorffer JN, Rivet J, Allard A, Bachelez H. Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br J Dermatol 2007; 156: 742–743.
Sanli H, Ataman S, Akay BN, Yilmaz A, Yildizlar D, Gürgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol 2007; 6: 834–836.
Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol 2005; 153: 207–208
Bucher C, Degen L, Dirnhofer S, Pless M, Herrmann R, Schraml P, et al. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 2005; 54: 732–733.
Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol 2009; 145: 94–95.
Gaulard P, Berti E, Willemze R, Jaffe ES. Primary cutaneous peripheral T-cell lymphomas, rare subtypes. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008, p. 302–303.
Jaffe ES, Ralfkiaer E. Subcutaneous panniculitis-like T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press; 2001, p. 212–213.
Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354–371.
Willemze R, Jansen P, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC cutaneous lymphoma group study of 83 cases. Blood 2008; 111: 838–845.
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433–1439.
Beyer M, Steinhoff M, Anagnostopoulos I, Assaf C, Sterry W. Hepatosplenic T-cell lymphomas and therapy with TNF-α-blocking biologics: a risk for psoriasis patients? J Dtsch Dermatol Ges 2009; 7: 191–194.
Share with your friends
Actions
Supplementary
There is no supplementary for this article.
Print information
Volume 89, Issue 6
DOI: 10.2340/00015555-0728
Pages:
653-654
View at PubMed